Could bacteria in breast tumors predict who responds to cancer therapy?

NCT ID NCT06709651

Recruiting now Knowledge-focused Sponsor: University College Cork Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at bacteria living in breast tumors of people with triple negative breast cancer. Researchers want to see if these bacteria can help predict who will respond well to chemotherapy and immunotherapy before surgery. The study will collect tumor samples before and after treatment from 30 participants to analyze changes in the microbiome.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a new way to predict which patients will respond to chemotherapy and immunotherapy, helping tailor treatment for triple negative breast cancer.
What could go wrong: This is a small, early-stage observational study with only 30 participants. It is not testing a treatment, so it may not directly change patient care. The findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Cork University Hospital
RECRUITING

Cork, Munster, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.